CN114302725A - 用于治疗细菌感染的β内酰胺抗生素和阿维巴坦衍生物的口服施用组合 - Google Patents

用于治疗细菌感染的β内酰胺抗生素和阿维巴坦衍生物的口服施用组合 Download PDF

Info

Publication number
CN114302725A
CN114302725A CN202080060861.2A CN202080060861A CN114302725A CN 114302725 A CN114302725 A CN 114302725A CN 202080060861 A CN202080060861 A CN 202080060861A CN 114302725 A CN114302725 A CN 114302725A
Authority
CN
China
Prior art keywords
substituted
oxy
radical
group
hydrocarbyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080060861.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·特里亚斯
C·萨布尔
A·尼科尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alisa Pharmaceutical Co
Original Assignee
Alisa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alisa Pharmaceutical Co filed Critical Alisa Pharmaceutical Co
Publication of CN114302725A publication Critical patent/CN114302725A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080060861.2A 2019-08-29 2020-08-27 用于治疗细菌感染的β内酰胺抗生素和阿维巴坦衍生物的口服施用组合 Pending CN114302725A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893612P 2019-08-29 2019-08-29
US62/893612 2019-08-29
US201962953852P 2019-12-26 2019-12-26
US62/953852 2019-12-26
PCT/US2020/048119 WO2021041616A1 (en) 2019-08-29 2020-08-27 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Publications (1)

Publication Number Publication Date
CN114302725A true CN114302725A (zh) 2022-04-08

Family

ID=72433031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060861.2A Pending CN114302725A (zh) 2019-08-29 2020-08-27 用于治疗细菌感染的β内酰胺抗生素和阿维巴坦衍生物的口服施用组合

Country Status (11)

Country Link
US (3) US20210060033A1 (enExample)
EP (1) EP4021443A1 (enExample)
JP (1) JP7673052B2 (enExample)
KR (1) KR20220054364A (enExample)
CN (1) CN114302725A (enExample)
AU (2) AU2020337449A1 (enExample)
BR (1) BR112022001344A2 (enExample)
CA (1) CA3152300C (enExample)
IL (1) IL290260A (enExample)
MX (1) MX2022002537A (enExample)
WO (1) WO2021041616A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115448920A (zh) * 2022-10-14 2022-12-09 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
CN116327764A (zh) * 2023-04-06 2023-06-27 复旦大学附属华山医院 一种高效广谱抗耐药菌的药物组合物及其制备方法和其应用
CN119431373A (zh) * 2024-07-24 2025-02-14 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途
CN119841826A (zh) * 2024-09-30 2025-04-18 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
EP4319760A4 (en) * 2021-04-05 2025-01-08 Qpex Biopharma, Inc. CEFTIBUTENE DOSAGE REGIMEN
JP2024524372A (ja) * 2021-07-01 2024-07-05 キューペックス バイオファーマ， インコーポレイテッド セフチブテンの結晶形態
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
WO2026104587A1 (en) 2024-11-13 2026-05-21 Adjutec Pharma As Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208557A1 (en) * 2017-05-10 2018-11-15 Arixa Pharmaceuticals, Inc. 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046845A1 (en) * 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
MX2020004071A (es) 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208557A1 (en) * 2017-05-10 2018-11-15 Arixa Pharmaceuticals, Inc. 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC M. GORDON ET AL.: "Orally Absorbed Derivatives of the β‑Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs", 《J. MED. CHEM. 》, vol. 61, pages 10340, XP055642182, DOI: 10.1021/acs.jmedchem.8b01389 *
LEONARD R. DUNCAN ET AL.: "Ceftibuten-Avibactam Activity against β-Lactam-Resistant Enterobacteriaceae Clinical Isolates", pages 1, Retrieved from the Internet <URL:https://www.jmilabs.com/data/posters/ASM-Microbe19-ceftibuten-avibactam.pdf?x21092> *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115448920A (zh) * 2022-10-14 2022-12-09 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
CN116327764A (zh) * 2023-04-06 2023-06-27 复旦大学附属华山医院 一种高效广谱抗耐药菌的药物组合物及其制备方法和其应用
CN116327764B (zh) * 2023-04-06 2024-04-12 浙江医药股份有限公司新昌制药厂 一种高效广谱抗耐药菌的药物组合物及其制备方法和其应用
CN119431373A (zh) * 2024-07-24 2025-02-14 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途
WO2026020683A1 (zh) * 2024-07-24 2026-01-29 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途
CN119841826A (zh) * 2024-09-30 2025-04-18 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用
CN119841826B (zh) * 2024-09-30 2026-04-10 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用

Also Published As

Publication number Publication date
KR20220054364A (ko) 2022-05-02
EP4021443A1 (en) 2022-07-06
WO2021041616A1 (en) 2021-03-04
US20230210863A1 (en) 2023-07-06
US20210060033A1 (en) 2021-03-04
US20260158040A1 (en) 2026-06-11
CA3152300C (en) 2024-04-30
BR112022001344A2 (pt) 2022-06-07
MX2022002537A (es) 2022-03-22
AU2024201877A1 (en) 2024-04-11
AU2024201877B2 (en) 2025-05-08
CA3152300A1 (en) 2021-03-04
JP7673052B2 (ja) 2025-05-08
IL290260A (en) 2022-04-01
AU2020337449A1 (en) 2022-03-03
JP2022545291A (ja) 2022-10-26

Similar Documents

Publication Publication Date Title
AU2024201877B2 (en) Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections
IL296379B1 (en) Beta-lactamase inhibitors and their uses
US11008321B2 (en) Crystalline form of an avibactam derivative
MX2009000116A (es) Profarmacos de penem.
JP2025163188A (ja) マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与
RU2825281C1 (ru) Вводимые перорально комбинации бета-лактамных антибиотиков и производных авибактама для лечения бактериальных инфекций
HK40072825A (en) Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infections
JP7437847B2 (ja) レレバクタムの誘導体およびその使用
HK40083209A (en) Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections
HK40063686A (en) Crystalline form of an avibactam derivative
JP2023525280A (ja) 環縮合２－ピリドン化合物、その調製方法、並びにグラム陽性菌が関与する疾患の治療及び／又は予防におけるそれらの使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072825

Country of ref document: HK